Notably, the inhibitory effect of brusatol on HER2-AKT/ERK1/2 signaling pathway in HER2-positive cancer cells was identified as a new mechanism, suggesting a therapeutic advantage for the use of brusatol in cancer therapy. The gene discussed is ERBB2; the disease is cancer.